{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T14:06:26Z","timestamp":1771682786352,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jns.2026.125769","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:11:13Z","timestamp":1769818273000},"page":"125769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Considerations on comorbidity, chronic intravenous immunoglobulins, and methodological clarifications on ZILU25 study"],"prefix":"10.1016","volume":"482","author":[{"given":"Vincenzo","family":"Di Stefano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicasio","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Frangiamore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2026.125769_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur J Neurol [Internet]."},{"key":"10.1016\/j.jns.2026.125769_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","author":"Di Stefano","year":"2024","journal-title":"Neurol Sci [Internet]."},{"issue":"5","key":"10.1016\/j.jns.2026.125769_bb0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol [Internet]."},{"key":"10.1016\/j.jns.2026.125769_bb0020","article-title":"Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study","volume":"479","author":"Di Stefano","year":"2025","journal-title":"J Neurol Sci [Internet]"},{"issue":"9","key":"10.1016\/j.jns.2026.125769_bb0025","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/13524585231189670","article-title":"Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: a scoping review","volume":"29","author":"Finlayson","year":"2023","journal-title":"Mult Scler [Internet]"},{"issue":"9","key":"10.1016\/j.jns.2026.125769_bb0030","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/j.1532-5415.2010.03032.x","article-title":"Fighting against age discrimination in clinical trials","volume":"58","author":"Cherubini","year":"2010","journal-title":"J Am Geriatr Soc [Internet]."},{"key":"10.1016\/j.jns.2026.125769_bb0035","article-title":"Comments on ZILU25: real-world efficacy of Zilucoplan in generalized myasthenia gravis","volume":"481","author":"Zheng","year":"2026","journal-title":"J Neurol Sci [Internet]."},{"issue":"8","key":"10.1016\/j.jns.2026.125769_bb0040","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol [Internet]."},{"issue":"12","key":"10.1016\/j.jns.2026.125769_bb0045","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol [Internet]."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:31:43Z","timestamp":1771680703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2600050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":9,"alternative-id":["S0022510X2600050X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125769","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations on comorbidity, chronic intravenous immunoglobulins, and methodological clarifications on ZILU25 study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125768","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125769"}}